Evaluating Sarcopenia by Using the Bioelectrical Impedance Analysis in Patients with Acute Myeloid Leukemia After Chemotherapy
Zheng Qin,Kai Lu,Tiantian Jiang,Mei Wang,Yue Weng,Xiaoqiong Tang,Yu Zhao
DOI: https://doi.org/10.2147/IJGM.S351241
IF: 2.145
2022-02-09
International Journal of General Medicine
Abstract:Zheng Qin, 1 Kai Lu, 2 Tiantian Jiang, 3 Mei Wang, 3 Yue Weng, 3 Xiaoqiong Tang, 3 Yu Zhao 1 1 Department of Vascular Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China; 2 Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China; 3 Department of hematopathology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China Correspondence: Xiaoqiong Tang Department of Hematopathology, The First Affiliated Hospital of Chongqing Medical University, 1 Youyi Road, Yuzhong, Chongqing, 400016, People's Republic of China , Email Yu Zhao Department of Vascular Surgery, The First Affiliated Hospital of Chongqing Medical University, 1 Youyi Road, Yuzhong, Chongqing, 400016, People's Republic of China , Email Background: We aimed to explore the potential association of body composition parameters measured by bioelectrical impedance analysis (BIA) with the incidence of sarcopenia in patients with acute myeloid leukemia (AML) (non-M3) after chemotherapy. Patients and Methods: This was a single-center observational study. Sixty-nine patients with newly diagnosed AML underwent BIA at the time of initial diagnosis and after completion of three chemotherapy sessions. Pre- and post-chemotherapy BIA parameters were compared. Sarcopenia was defined as low skeletal muscle mass plus low muscle strength according to the Asian Working Group for Sarcopenia (AWGS). Association of sarcopenia with mid-arm muscle circumference (MAMC) and intracellular water (ICW) was assessed by multivariate logistic regression. Results: There was a significant increase in the prevalence of sarcopenia after chemotherapy (39.1% vs 14.5%, P < 0.001). Skeletal muscle mass (SMM), fat-free mass (FFM), and soft lean mass (SLM) showed a significant decrease after chemotherapy ( P < 0.05). MAMC, ICW, and total body water (TBW) significantly decreased after chemotherapy ( P < 0.05). BIA indices including appendicular skeletal muscle mass (ASM) ( r =0.889, P < 0.001), ICW ( r =0.869, P < 0.001), MAMC ( r =0.849, P < 0.001) showed a positive correlation with SMI. Moreover, ASM ( r =− 0.453 P =0.001), ICW ( r =− 0.322, P < 0.05), and MAMC ( r =− 0.352, P < 0.05) showed a negative correlation with sarcopenia. On multivariate logistic regression analysis, increased ICW was associated with decreased risk of sarcopenia [odds ratio (OR): 0.50; 95% confidence interval (CI) 0.30– 0.82]. Each additional unit of MAMC after chemotherapy was associated with 71% lower risk of sarcopenia (OR: 0.29; 95% CI 0.13– 0.66). Conclusion: The incidence of sarcopenia was associated with chemotherapy of patients with AML (non-M3) as reflected by body composition changes. Keywords: acute myeloid leukemia, sarcopenia, bioelectrical impedance analysis, mid-arm muscle circumference Acute myeloid leukemia (AML) is one of the most common forms of leukemia in adults. 1 In the absence of treatment, death usually occurs within months of diagnosis secondary to infection or bleeding. 2 Chemotherapy is the main treatment modality for AML. However, the side effects of chemotherapy, including body composition disorders, dramatically decrease the quality of life and lead to poor prognosis. 3 Therefore, prevention and early detection of post-chemotherapy changes in body composition is a key imperative for AML patients. Muscle wasting is a critical component of the change in body composition. Sarcopenia is characterized by severe loss of muscle mass and decline in muscle function. 4 The incidence of sarcopenia in elderly patients with hematologic malignancies, especially in non-Hodgkin's lymphoma (NHL), is higher than general elderly population. 5 Several studies have corroborated the poor prognostic impact of sarcopenia and body composition changes in patients with various solid cancers. 6–8 Sun et al reported that progress of sarcopenia in patients with AML is associated with adverse outcomes, and the overall survival (OS) of patients with sarcopenia was shorter than non-sarcopenia patients. 9 Bioelectrical impedance analysis (BIA) has been widely used to evaluate body composition in various clinical fields. 10 Devices for BIA have a high accuracy and efficiency for evaluation of body composition at a relatively low cost. 11 In the contemporary literature, changes in body composition and -Abstract Truncated-
medicine, general & internal